Sökning: onr:"swepub:oai:DiVA.org:umu-203081" >
Treatment Patterns ...
Treatment Patterns among Patients with Atopic Dermatitis in Secondary Care : A National, Observational, Non-interventional, Retrospective Study in Sweden
-
- Johansson, Emma K. (författare)
- Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
-
- Brenneche, Andreas (författare)
- Nordic Market Access, LEO Pharma AB, Malmö, Sweden
-
- Trangbaek, Dennis (författare)
- Nordic Medical Affairs, LEO Pharma AB, Malmö, Sweden
-
visa fler...
-
- Stelmaszuk, M. Natalia (författare)
- Real-World Evidence, Parexel International Limited, Stockholm, Sweden,Parexel Int Ltd, Sweden
-
- Freilich, Jonatan (författare)
- Umeå universitet,Avdelningen för medicin,Real-World Evidence, Parexel International Limited, Stockholm, Sweden,Parexel Int Ltd, Sweden; Umea Univ, Sweden
-
- Anderson, Chris (författare)
- Linköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Hudkliniken i Östergötland
-
visa färre...
-
(creator_code:org_t)
- 2022-09-06
- 2022
- Engelska.
-
Ingår i: Acta Dermato-Venereologica. - : Medical Journals Sweden AB. - 0001-5555 .- 1651-2057. ; 102
- Relaterad länk:
-
https://doi.org/10.2...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- This non-interventional, observational, longitudinal study describes treatment patterns of atopic dermatitis (AD) in Sweden. Data from 3 Swedish registries were merged, and included patients who received an AD diagnosis (during the period 1997 to 2019) and had AD treatment prescribed (during the period 2006 to 2020). Treatment persistence, treatment sequen-cing, time-to-event analysis, and 12-month prevalence were analysed. Overall, data for 99,885 patients with AD were included, of whom 4,086 (4.1%) received systemic treatments. Median persistence rates were 12.6 (95% CI 11.9, 13.4) months for methotrexate, 10.8 (9.1, 13.0) months for azathioprine, 5.6 (3.8, 6.2) months for mycophenolate, 5.1 (4.4, 5.7) months for alitretinoin and 3.4 (3.2, 3.7) months for cyclosporine. Median (Q1, Q3) time from first secondary care visit for AD to first systemic treatment was 5.8 (2.2, 11.0) years overall and 4.4 (1.3, 9.1) years in the Stockholm region. Methotrexate was a prominent first-and second-line treatment used during the period 2006 to 2020. Dupilumab was introduced during the study period and was increasingly used as first-or second-line therapy over time. The 12-month prevalence of AD generally remained steady, with a gradual increase observed over time for the overall population. A steep increase was observed in Stockholm from 2011. This study shows that a small proportion of patients with AD are offered systemic treatments in Sweden, with long periods in secondary care prior to systemic treatments and low persistence on systemic treatments. Regional differences highlight a need for national treatment guidelines.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- atopic dermatitis
- atopic eczema
- dispensed prescription
- epide-miology
- registry
- treatment patterns
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas